Over a week ago |
Recommendations
|
After getting inbound… After getting inbound inquires from investors on the WSJ article about Pfizer (PFE) being in advanced talks to buy Global Blood Therapeutics (GBT) for $5B, Truist analyst Joon Lee noted that Pfizer does not have a sickle cell franchise, but said that Oxbryta and pipeline drug GBT601 "should be more broadly considered as anemia drugs" so Global Blood "could be a good complement to any pharma" company with an oncology franchise. Merck (MRK), Bristol-Myers (BMY), Novo Nordisk (NVO), Vertex (VRTX) and Novartis (NVS) may also make sense as an acquirer, added Lee. Regarding the reported valuation of $5B, a takeout price would be in the $59 range assuming pending options, convertible notes and RSUs are included, but if based only on the basic share count figure, that market cap value would equate to a $77 per share price, said the analyst, who awaits further clarity. Lee has a Buy rating and $50 price target on Global Blood shares, which are up $17.70, or 37%, to $65.69 in afternoon trading. ShowHide Related Items >><< VRTX Vertex Pharmaceuticals - $286.79 /
+12.83 (+4.68%) - 08/04/22
- Vertex Pharmaceuticals raises FY22 product revenue view to $8.6B-$8.8B
- 07/22/22
- Vertex Pharmaceuticals plans to advance VX-548 into Phase 3 clinical trials
- 07/20/22
- Vertex Pharmaceuticals, Verve Therapeutics enter exclusive research pact
- 07/11/22
- Vertex Pharmaceuticals to acquire ViaCyte for $320M in cash
- 07/29/22
- ViiV Healthcare presents five-year data at AIDS 2022 on fostemsavir
- 07/28/22
- ViiV Healthcare announces data from unblinded phase of HPTN 084 study
- 07/28/22
- Bausch Health to appeal expected court decision on certain Xifaxan patents
- 07/25/22
- Novartis says FDA has accepted BLA for proposed biosimilar natalizumab
- 07/21/22
- FDA accepts Sandoz supplemental BLA for high concentration biosimilar Hyrimoz
- 07/20/22
- Ionis Pharmaceuticals completes enrollment of Phase 3 Lp(a) HORIZON study
- $103.06 /
-1.465 (-1.40%) - 07/29/22
- Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials
- 07/11/22
- Novo Nordisk says phase 1 & 2 FRONTIER1 study met primary safety endpoint
- 07/10/22
- Novo Nordisk announces Phase 3 results of explorer7 study
- 06/22/22
- Novo Nordisk, Echosens announce partnership to increase early diagnosis of NASH
- 08/04/22
- AstraZeneca, Merck: EC approves LYNPARZA to treat BRCA1/2 mutations
- 08/04/22
- AstraZeneca's lynparza approved in EU for early breast cancer therapy
- 08/03/22
- Merck, Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
- 08/03/22
- Merck says Phase 3 KEYNOTE-921 trial did not meet dual primary endpoints
GBT Global Blood Therapeutics - $66.20 /
+18.21 (+37.95%) - 08/05/22
- Global Blood Therapeutics trading resumes
- 08/05/22
- Fulcrum Therapeutics up 8% after WSJ says Pfizer in talks to buy Global Blood
- 08/05/22
- Global Blood up 10% and halted after WSJ report of Pfizer deal talks
- 08/05/22
- Global Blood Therapeutics trading halted, volatility trading pause
- 07/29/22
- Bristol-Myers: Part A of CheckMate -914 trial did not meet primary endpoint
- 07/26/22
- Evogene's Biomica doses first patient in Phase I clinical trial of BMC128
- 07/22/22
- Bristol-Myers reports positive CHMP opinion for nivolumab/relatlimab combination
- 07/21/22
- Bristol-Myers announces biopharma collaboration with Jack and Jill of America
GBT Global Blood Therapeutics - $66.20 /
+18.21 (+37.95%) - 08/04/22 Truist
- Truist sees Novartis, Vertex as logical suitors for Global Blood
- 06/28/22 JPMorgan
- Global Blood Therapeutics price target lowered to $36 from $39 at JPMorgan
- 05/11/22 Wedbush
- Global Blood Therapeutics added to Best Ideas List at Wedbush
- 05/05/22 Oppenheimer
- Global Blood Therapeutics price target lowered to $71 from $86 at Oppenheimer
- 08/01/22 Jefferies
- Concert Pharmaceuticals price target raised to $14 from $9.50 at Jefferies
- 08/01/22 Barclays
- Pfizer price target raised to $52 from $50 at Barclays
- 07/22/22 Piper Sandler
- Piper says Pfizer expansion into Crohn's ups conviction in Prometheus drug
- 07/18/22 Cowen
- Cowen believes Global Pharma quarterly results will be strong
- 07/29/22 Barclays
- Merck price target raised to $101 from $97 at Barclays
- 07/27/22 H.C. Wainwright
- Seagen price target raised to $200 from $170 at H.C. Wainwright
- 07/18/22 UBS
- Merck price target raised to $98 from $76 at UBS
- 07/12/22 H.C. Wainwright
- H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
- 08/05/22 Jefferies
- Jefferies downgrades Compugen to Hold with cash likely becoming 'growing issue'
- 08/04/22 Stifel
- Compugen price target lowered to $5 from $12 at Stifel
- 07/28/22 JPMorgan
- Bristol-Myers price target raised to $85 from $80 at JPMorgan
- 07/20/22 Canaccord
- Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
- $103.06 /
-1.465 (-1.40%) - 08/04/22 Barclays
- Novo Nordisk price target lowered to DKK 825 from DKK 875 at Barclays
- 08/03/22 Piper Sandler
- Piper says Altimmune selloff related to Novo continuing Phase 3 SELECT trial
- 07/15/22 Morgan Stanley
- Novo Nordisk upgraded to Overweight from Equal Weight at Morgan Stanley
- 06/28/22 UBS
- Novo Nordisk downgraded to Sell from Neutral at UBS
- 07/20/22 JPMorgan
- Novartis price target raised to CHF 81 from CHF 80 at JPMorgan
- 07/20/22 Piper Sandler
- Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
- 06/29/22 Deutsche Bank
- Novartis price target lowered to CHF 75 from CHF 80 at Deutsche Bank
VRTX Vertex Pharmaceuticals - $286.79 /
+12.83 (+4.68%) - 08/05/22 H.C. Wainwright
- Vertex Pharmaceuticals price target raised to $300 from $275 at H.C. Wainwright
- 08/05/22 Barclays
- Vertex Pharmaceuticals price target raised to $307 from $291 at Barclays
- 07/26/22 Piper Sandler
- Vertex Pharmaceuticals price target raised to $256 from $242 at Piper Sandler
VRTX Vertex Pharmaceuticals - $286.79 /
+12.83 (+4.68%) - 08/04/22
- Vertex Pharmaceuticals reports Q2 adjusted EPS $3.60, consensus $3.48
- 05/05/22
- Vertex Pharmaceuticals reports Q1 adjusted EPS $3.52, consensus $3.49
- 05/05/22
- Notable companies reporting after market close
- 07/28/22
- Pfizer raises FY22 adjusted EPS view to $6.30-$6.45 from $6.25-$6.45
- 07/28/22
- Pfizer reports Q2 adjusted EPS $2.04, consensus $1.80
- 07/27/22
- Notable companies reporting before tomorrow's open
- 07/19/22
- Novartis reports Q2 core EPS $1.56 vs. $1.66 a year ago
- 04/26/22
- Novartis sees 2022 core operating income to grow mid single digit
- 04/26/22
- Novartis reports Q1 core EPS $1.46, consensus $1.46
- $103.06 /
-1.465 (-1.40%) - 08/03/22
- Novo Nordisk raises 2022 sales growth outlook to 12%-16%
- 08/03/22
- Novo Nordisk reports Q2 EBIT DKK 18.39B, consensus DKK 18.13B
- 04/29/22
- Novo Nordisk now sees 2022 sales growth of 10%-14% at CER
- 04/29/22
- Novo Nordisk reports Q1 EPS DKK 6.22 vs. DKK 5.45 last year
- 07/28/22
- Merck narrows FY22 adjusted EPS view to $7.25-$7.35 from $7.24-$7.36
- 07/28/22
- Merck reports Q2 adjusted EPS $1.87, consensus $1.69
GBT Global Blood Therapeutics - $66.20 /
+18.21 (+37.95%) - 05/04/22
- Global Blood Therapeutics reports Q1 EPS ($1.26), consensus ($1.30)
- 02/24/22
- Global Blood Therapeutics reports Q4 EPS ($1.36), consensus ($1.13)
- 07/27/22
- Bristol-Myers sees FY22 adjusted EPS $7.44-$7.74, consensus $7.46
- 07/27/22
- Bristol-Myers reports Q2 adjusted EPS $1.93, consensus $1.79
- 07/26/22
- Notable companies reporting before tomorrow's open
- 07/18/22
- GSK CEO says split will help deal with 'perennial underperformance,' FT reports
- 06/28/22
- FDA panel recommends omicron update for COVID vaccine boosters, CNBC says
- 06/30/22
- Novartis favoring spinoff of $25B Sandoz unit, Bloomberg reports
- 06/30/22
- Novartis said to lean toward Sandoz spinoff over sale, Bloomberg says
- 06/28/22
- Novartis to cut up to 8,000 jobs, or 7% of workforce, in restructuring
- 06/28/22
- Novartis planning to cut up to 1,400 jobs in Switzerland, Reuters reports
- $103.06 /
-1.465 (-1.40%) - 07/09/22
- Eli Lilly's growth set to soar under CEO Ricks, Barron's says
- 07/27/22
- Senate panel says Merck avoided billions in U.S. taxes on Keytruda, Reuters says
- 07/15/22
- Merck deal for Seagen unlikely to be completed by earnings, WSJ reports
- 07/07/22
- Merck offers around $200 per share for Seagen, FT reports
- 07/07/22
- Merck in advanced talks to buy Seagen for $40B+, WSJ reports
GBT Global Blood Therapeutics - $66.20 /
+18.21 (+37.95%) - 08/05/22
- Pfizer in advanced talks to buy Global Blood for about $5B, WSJ reports
- 08/05/22
- Pfizer in talks to buy Global Blood Therapeutics for about $5B, WSJ says
- 06/24/22
- Judge says Bristol-Myers must face $6.4B Breyanzi lawsuit, Reuters says
- 06/14/22
- FTC asked to investigate price hikes by Janssen, Bristol-Myers, STAT says
- 05/28/22
- Buy Bristol-Myers, rally just getting started, Barron's says
VRTX Vertex Pharmaceuticals - $286.79 /
+12.83 (+4.68%) - 06/01/22
- What You Missed On Wall Street On Wednesday
- 06/01/22
- What You Missed On Wall Street This Morning
- 06/01/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/23/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 07/21/22
- What You Missed On Wall Street On Thursday
- 07/21/22
- What You Missed On Wall Street This Morning
- 06/30/22
- What You Missed On Wall Street On Thursday
- 06/30/22
- What You Missed On Wall Street This Morning
- 06/28/22
- What You Missed On Wall Street On Tuesday
- $103.06 /
-1.465 (-1.40%) - 07/15/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 07/28/22
- What You Missed On Wall Street On Thursday
- 07/28/22
- What You Missed On Wall Street This Morning
- 07/20/22
- What You Missed On Wall Street On Wednesday
- 07/20/22
- What You Missed On Wall Street This Morning
GBT Global Blood Therapeutics - $66.20 /
+18.21 (+37.95%) - 08/05/22
- What You Missed On Wall Street This Morning
- 08/04/22
- What You Missed On Wall Street On Thursday
- 08/04/22
- What You Missed On Wall Street This Morning
- 04/28/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 07/27/22
- Fly Intel: Pre-market Movers
- 07/20/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 06/24/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 06/06/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
VRTX Vertex Pharmaceuticals - $286.79 /
+12.83 (+4.68%) - 07/05/22
- Early notable gainers among liquid option names on July 5th
- 07/28/22
- Unusually active option classes on open July 28th
- 06/30/22
- Early notable gainers among liquid option names on June 30th
- 05/20/22
- Early notable gainers among liquid option names on May 20th
- 04/26/22
- Unusually active option classes on open April 26th
- $103.06 /
-1.465 (-1.40%) - 04/11/22
- Largest borrow rate increases among liquid names
- 04/07/22
- Largest borrow rate increases among liquid names
- 04/05/22
- Largest borrow rate increases among liquid names
- 04/04/22
- Largest borrow rate increases among liquid names
- 07/11/22
- Early notable gainers among liquid option names on July 11th
- 07/11/22
- Unusually active option classes on open July 11th
- 07/06/22
- Unusually active option classes on open July 6th
- 06/01/22
- Merck put volume heavy and directionally bearish
- 06/02/22
- Unusually active option classes on open June 2nd
- 02/16/22
- Bristol Myers Squibb call volume above normal and directionally bullish
|
Hot Stocks
|
AstraZeneca (AZN) and… AstraZeneca (AZN) and Merck (MRK) announced that the European Commission has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm), who have human epidermal growth factor receptor 2-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. ShowHide Related Items >><< - 08/04/22
- AstraZeneca's lynparza approved in EU for early breast cancer therapy
- 08/03/22
- Merck, Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
- 08/03/22
- Merck says Phase 3 KEYNOTE-921 trial did not meet dual primary endpoints
- 08/01/22
- ALX Oncology's evorpacept receives FTD from FDA
- 08/01/22
- Innate Pharma, AstraZeneca to discontinue INTERLINK-1 Phase 3 study
- 07/29/22
- AstraZeneca says Demare to succeed Johansson as Non-Executive Chair
- 07/25/22
- AstraZeneca's Tezspire recommended for approval in E.U. by CHMP in severe asthma
- 07/29/22 Barclays
- Merck price target raised to $101 from $97 at Barclays
- 07/27/22 H.C. Wainwright
- Seagen price target raised to $200 from $170 at H.C. Wainwright
- 07/18/22 UBS
- Merck price target raised to $98 from $76 at UBS
- 07/12/22 H.C. Wainwright
- H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
- 08/01/22 JPMorgan
- AstraZeneca price target raised to 12,500 GBp from 12,000 GBp at JPMorgan
- 08/01/22 Deutsche Bank
- AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Deutsche Bank
- 07/29/22 Stifel
- Zentalis loses top competitor with AstraZeneca discontinuation, says Stifel
- 07/12/22 Citi
- AstraZeneca price target raised to 13,000 GBp from 10,500 GBp at Citi
- 07/28/22
- Merck narrows FY22 adjusted EPS view to $7.25-$7.35 from $7.24-$7.36
- 07/28/22
- Merck reports Q2 adjusted EPS $1.87, consensus $1.69
- 07/27/22
- Notable companies reporting before tomorrow's open
- 07/29/22
- AstraZeneca backs FY22 core EPS view up by mid to high twenties percentage
- 07/29/22
- AstraZeneca reports Q2 core EPS $1.72, up 89% year-over-year
- 04/29/22
- AstraZeneca backs FY22 core EPS up by mid to high twenties percentage
- 04/29/22
- AstraZeneca reports Q1 core EPS $1.89, up 20% y/y
- 07/27/22
- Senate panel says Merck avoided billions in U.S. taxes on Keytruda, Reuters says
- 07/15/22
- Merck deal for Seagen unlikely to be completed by earnings, WSJ reports
- 07/07/22
- Merck offers around $200 per share for Seagen, FT reports
- 07/07/22
- Merck in advanced talks to buy Seagen for $40B+, WSJ reports
- 06/17/22
- AstraZeneca considering bid for Mereo BioPharma, U.K. Times reports
- 05/10/22
- Emergent plant's quality problems led to 400M discarded vaccines, WSJ reports
- 03/23/22
- AstraZeneca preventive COVID shot set to win EU clearance, Reuters says
- 07/28/22
- What You Missed On Wall Street On Thursday
- 07/28/22
- What You Missed On Wall Street This Morning
- 07/20/22
- What You Missed On Wall Street On Wednesday
- 07/20/22
- What You Missed On Wall Street This Morning
- 07/05/22
- Fly Intel: Pre-market Movers
- 05/24/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 04/06/22
- Fly Intel: Pre-market Movers
- 03/23/22
- What You Missed On Wall Street On Wednesday
- 07/11/22
- Early notable gainers among liquid option names on July 11th
- 07/11/22
- Unusually active option classes on open July 11th
- 07/06/22
- Unusually active option classes on open July 6th
- 06/01/22
- Merck put volume heavy and directionally bearish
- 07/20/22
- AstraZeneca call volume above normal and directionally bullish
- 06/06/22
- Unusually active option classes on open June 6th
- 04/26/22
- AstraZeneca call volume above normal and directionally bullish
- 04/07/22
- AstraZeneca put volume heavy and directionally bearish
|
Hot Stocks
|
AstraZeneca (AZN) and… AstraZeneca (AZN) and MSD's (MRK) Lynparza, or olaparib, has been approved in the European Union as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations, who have human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. This approval by the European Commission was based on results from the OlympiA Phase III trial published in The New England Journal of Medicine in June 2021 and follows the recommendation for approval in the EU by the Committee for Medicinal Products for Human Use of Lynparza in this setting.1 In the trial, Lynparza demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS), reducing the risk of invasive breast cancer recurrences, new cancers, or death by 42% versus placebo. Lynparza also demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), reducing the risk of death by 32% versus placebo (based on a HR of 0.68; 98.5% CI 0.47-0.97; p=0.009). The safety and tolerability profile of Lynparza in this trial was in line with that observed in prior clinical trials. Reference Link ShowHide Related Items >><< - 08/03/22
- Merck, Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
- 08/03/22
- Merck says Phase 3 KEYNOTE-921 trial did not meet dual primary endpoints
- 08/01/22
- ALX Oncology's evorpacept receives FTD from FDA
- 07/26/22
- Sutro:1st patient dosed in study with Merck for cytokine derivative for cancer
- 08/01/22
- Innate Pharma, AstraZeneca to discontinue INTERLINK-1 Phase 3 study
- 07/29/22
- AstraZeneca says Demare to succeed Johansson as Non-Executive Chair
- 07/25/22
- AstraZeneca's Tezspire recommended for approval in E.U. by CHMP in severe asthma
- 07/25/22
- AstraZeneca's Utomiris recommended for approval in E.U. by CHMP
- 08/01/22 JPMorgan
- AstraZeneca price target raised to 12,500 GBp from 12,000 GBp at JPMorgan
- 08/01/22 Deutsche Bank
- AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Deutsche Bank
- 07/29/22 Stifel
- Zentalis loses top competitor with AstraZeneca discontinuation, says Stifel
- 07/12/22 Citi
- AstraZeneca price target raised to 13,000 GBp from 10,500 GBp at Citi
- 07/29/22 Barclays
- Merck price target raised to $101 from $97 at Barclays
- 07/27/22 H.C. Wainwright
- Seagen price target raised to $200 from $170 at H.C. Wainwright
- 07/18/22 UBS
- Merck price target raised to $98 from $76 at UBS
- 07/12/22 H.C. Wainwright
- H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
- 07/28/22
- Merck narrows FY22 adjusted EPS view to $7.25-$7.35 from $7.24-$7.36
- 07/28/22
- Merck reports Q2 adjusted EPS $1.87, consensus $1.69
- 07/27/22
- Notable companies reporting before tomorrow's open
- 07/29/22
- AstraZeneca backs FY22 core EPS view up by mid to high twenties percentage
- 07/29/22
- AstraZeneca reports Q2 core EPS $1.72, up 89% year-over-year
- 04/29/22
- AstraZeneca backs FY22 core EPS up by mid to high twenties percentage
- 04/29/22
- AstraZeneca reports Q1 core EPS $1.89, up 20% y/y
- 07/27/22
- Senate panel says Merck avoided billions in U.S. taxes on Keytruda, Reuters says
- 07/15/22
- Merck deal for Seagen unlikely to be completed by earnings, WSJ reports
- 07/07/22
- Merck offers around $200 per share for Seagen, FT reports
- 07/07/22
- Merck in advanced talks to buy Seagen for $40B+, WSJ reports
- 06/17/22
- AstraZeneca considering bid for Mereo BioPharma, U.K. Times reports
- 05/10/22
- Emergent plant's quality problems led to 400M discarded vaccines, WSJ reports
- 03/23/22
- AstraZeneca preventive COVID shot set to win EU clearance, Reuters says
- 07/28/22
- What You Missed On Wall Street On Thursday
- 07/28/22
- What You Missed On Wall Street This Morning
- 07/20/22
- What You Missed On Wall Street On Wednesday
- 07/20/22
- What You Missed On Wall Street This Morning
- 07/05/22
- Fly Intel: Pre-market Movers
- 05/24/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 04/06/22
- Fly Intel: Pre-market Movers
- 03/23/22
- What You Missed On Wall Street On Wednesday
- 07/11/22
- Early notable gainers among liquid option names on July 11th
- 07/11/22
- Unusually active option classes on open July 11th
- 07/06/22
- Unusually active option classes on open July 6th
- 06/01/22
- Merck put volume heavy and directionally bearish
- 07/20/22
- AstraZeneca call volume above normal and directionally bullish
- 06/06/22
- Unusually active option classes on open June 6th
- 04/26/22
- AstraZeneca call volume above normal and directionally bullish
- 04/07/22
- AstraZeneca put volume heavy and directionally bearish
|
Hot Stocks
|
Merck (MRK) and Eisai… Merck (MRK) and Eisai (ESALY) announced that the Phase 3 LEAP-002 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, versus LENVIMA monotherapy did not meet its dual primary endpoints of overall survival and progression-free survival as a first-line treatment for patients with unresectable hepatocellular carcinoma. There were trends toward improvement in OS and PFS for patients who received KEYTRUDA plus LENVIMA versus LENVIMA monotherapy; however, these results did not meet statistical significance per the pre-specified statistical plan. The median OS of the LENVIMA monotherapy arm in LEAP-002 was longer than that observed in previously reported clinical trials evaluating LENVIMA monotherapy in uHCC. The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination. Merck and Eisai plan to present these data at an upcoming medical conference. ShowHide Related Items >><< - 08/03/22
- Merck says Phase 3 KEYNOTE-921 trial did not meet dual primary endpoints
- 08/01/22
- ALX Oncology's evorpacept receives FTD from FDA
- 07/26/22
- Sutro:1st patient dosed in study with Merck for cytokine derivative for cancer
- 07/26/22
- Astellas Pharma, Seagen announce topline results from EV-103 trial
- 07/05/22
- Biogen says FDA accepts BLA for lecanemab under accelerated approval pathway
- 05/09/22
- Eisai, Biogen complete rolling FDA submission for Lecanemab biologics license
- 03/28/22
- Galapagos reports Gilead, Eisai get MHLW approval for second Jyseleca indication
- 03/21/22
- Biogen announces latest findings on lecanemab
- 07/29/22 Barclays
- Merck price target raised to $101 from $97 at Barclays
- 07/27/22 H.C. Wainwright
- Seagen price target raised to $200 from $170 at H.C. Wainwright
- 07/18/22 UBS
- Merck price target raised to $98 from $76 at UBS
- 07/12/22 H.C. Wainwright
- H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
- 07/21/22 Truist
- Biogen price target lowered to $270 from $320 at Truist
- 04/08/22 William Blair
- CMS decision to substantially limit Biogen opportunity, says William Blair
- 03/28/22 BofA
- Biogen price target lowered to $225 from $230 at BofA
- 01/13/22 Citi
- Eisai downgraded to Neutral from Buy at Citi
- 07/28/22
- Merck narrows FY22 adjusted EPS view to $7.25-$7.35 from $7.24-$7.36
- 07/28/22
- Merck reports Q2 adjusted EPS $1.87, consensus $1.69
- 07/27/22
- Notable companies reporting before tomorrow's open
- 07/27/22
- Senate panel says Merck avoided billions in U.S. taxes on Keytruda, Reuters says
- 07/15/22
- Merck deal for Seagen unlikely to be completed by earnings, WSJ reports
- 07/07/22
- Merck offers around $200 per share for Seagen, FT reports
- 07/07/22
- Merck in advanced talks to buy Seagen for $40B+, WSJ reports
- 02/24/22
- Drugmakers criticize Medicare proposal on Biogen's Alzheimer's drug, WSJ says
- 07/28/22
- What You Missed On Wall Street On Thursday
- 07/28/22
- What You Missed On Wall Street This Morning
- 07/20/22
- What You Missed On Wall Street On Wednesday
- 07/20/22
- What You Missed On Wall Street This Morning
- 03/28/22
- Meet Citius: Fly exclusive interview with Executive Chairman Leonard Mazur
- 07/11/22
- Early notable gainers among liquid option names on July 11th
- 07/11/22
- Unusually active option classes on open July 11th
- 07/06/22
- Unusually active option classes on open July 6th
- 06/01/22
- Merck put volume heavy and directionally bearish
|
Hot Stocks
|
Merck announced that the… Merck announced that the Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA in combination with chemotherapy compared to chemotherapy alone did not meet its dual primary endpoints of overall survival, or OS, and radiographic progression-free survival, or rPFS, for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC. "In the study, there were modest trends toward an improvement in both OS and rPFS for patients who received KEYTRUDA plus chemotherapy compared with chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies. Results will be presented at an upcoming medical meeting," the company stated. "Results from this study serve as an important reminder that metastatic prostate cancer remains very difficult to treat, and more research is needed. We will continue to advance our clinical development program to evaluate KEYTRUDA-based combinations and novel candidates for patients with this disease," said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. ShowHide Related Items >><< - 08/01/22
- ALX Oncology's evorpacept receives FTD from FDA
- 07/26/22
- Sutro:1st patient dosed in study with Merck for cytokine derivative for cancer
- 07/26/22
- Astellas Pharma, Seagen announce topline results from EV-103 trial
- 07/20/22
- Merck says Phase 3 KEYNOTE-412 trial did not meet primary endpoint of EFS
- 07/29/22 Barclays
- Merck price target raised to $101 from $97 at Barclays
- 07/27/22 H.C. Wainwright
- Seagen price target raised to $200 from $170 at H.C. Wainwright
- 07/18/22 UBS
- Merck price target raised to $98 from $76 at UBS
- 07/12/22 H.C. Wainwright
- H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
- 07/28/22
- Merck narrows FY22 adjusted EPS view to $7.25-$7.35 from $7.24-$7.36
- 07/28/22
- Merck reports Q2 adjusted EPS $1.87, consensus $1.69
- 07/27/22
- Notable companies reporting before tomorrow's open
- 07/27/22
- Senate panel says Merck avoided billions in U.S. taxes on Keytruda, Reuters says
- 07/15/22
- Merck deal for Seagen unlikely to be completed by earnings, WSJ reports
- 07/07/22
- Merck offers around $200 per share for Seagen, FT reports
- 07/07/22
- Merck in advanced talks to buy Seagen for $40B+, WSJ reports
- 07/28/22
- What You Missed On Wall Street On Thursday
- 07/28/22
- What You Missed On Wall Street This Morning
- 07/20/22
- What You Missed On Wall Street On Wednesday
- 07/20/22
- What You Missed On Wall Street This Morning
- 07/11/22
- Early notable gainers among liquid option names on July 11th
- 07/11/22
- Unusually active option classes on open July 11th
- 07/06/22
- Unusually active option classes on open July 6th
- 06/01/22
- Merck put volume heavy and directionally bearish
|
Hot Stocks
|
ALX Oncology (ALXO)… ALX Oncology (ALXO) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD, to evorpacept, a next generation CD47 blocker, in combination with KEYTRUDA, Merck's (MRK) anti-PD-1 therapy, for the first-line treatment of adult patients with PD-L1 positive advanced head and neck squamous cell carcinoma, HNSCC. The FDA's decision is informed by the results of ALX Oncology's phase 1 clinical trial, ASPEN-01, that showed preliminary antitumor activity and a favorable safety profile in checkpoint inhibitor-naive patients with second-line or greater advanced HNSCC treated with evorpacept and pembrolizumab. "The FDA's Fast Track designation for the first-line treatment of HNSCC with evorpacept in combination with pembrolizumab builds upon evorpacept's prior Fast Track designation in the first-line HNSCC population in combination with pembrolizumab and standard chemotherapy highlighting the potential clinical utility of evorpacept in this difficult-to-treat disease," said Sophia Randolph, M.D., Ph.D., Chief Medical Officer, ALX Oncology. "We are pleased by the patient enrollment progress being made across our HNSCC phase 2 program as we seek to advance evorpacept to help patients living with this disease." ShowHide Related Items >><< - 07/26/22
- Sutro:1st patient dosed in study with Merck for cytokine derivative for cancer
- 07/26/22
- Astellas Pharma, Seagen announce topline results from EV-103 trial
- 07/20/22
- Merck says Phase 3 KEYNOTE-412 trial did not meet primary endpoint of EFS
- 07/18/22
- Merck to stop Phase 3 LYNK-003 trial investigating LYNPARZA
- 06/29/22
- ALX Oncology receives US FDA ODD for evorpacept
- 06/28/22
- ALX Oncology treatment of acute myeloid leukemia granted FDA orphan designation
- 06/03/22
- ALX Oncology expects results from ASPEN-06 study in 2023
- 06/03/22
- ALX Oncology expects results from ASPEN-03, ASPEN-04 studies by mid-2024
- 06/06/22 Stifel
- ALX Oncology price target lowered to $16 from $35 at Stifel
- 06/03/22 Piper Sandler
- ALX's evorpacept best-in-class aong CD47-targeting agents, says Piper Sandler
- 05/18/22 Piper Sandler
- ALX Oncology price target lowered to $48 from $70 at Piper Sandler
- 03/14/22 Cantor Fitzgerald
- ALX Oncology price target lowered to $60 from $103 at Cantor Fitzgerald
- 07/29/22 Barclays
- Merck price target raised to $101 from $97 at Barclays
- 07/27/22 H.C. Wainwright
- Seagen price target raised to $200 from $170 at H.C. Wainwright
- 07/18/22 UBS
- Merck price target raised to $98 from $76 at UBS
- 07/12/22 H.C. Wainwright
- H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
- 07/28/22
- Merck narrows FY22 adjusted EPS view to $7.25-$7.35 from $7.24-$7.36
- 07/28/22
- Merck reports Q2 adjusted EPS $1.87, consensus $1.69
- 07/27/22
- Notable companies reporting before tomorrow's open
- 05/09/22
- ALX Oncology reports Q1 EPS (60c), consensus (71c)
- 02/28/22
- ALX Oncology reports Q4 EPS (70c), consensus (62c)
- 07/27/22
- Senate panel says Merck avoided billions in U.S. taxes on Keytruda, Reuters says
- 07/15/22
- Merck deal for Seagen unlikely to be completed by earnings, WSJ reports
- 07/07/22
- Merck offers around $200 per share for Seagen, FT reports
- 07/07/22
- Merck in advanced talks to buy Seagen for $40B+, WSJ reports
- 07/28/22
- What You Missed On Wall Street On Thursday
- 07/28/22
- What You Missed On Wall Street This Morning
- 07/20/22
- What You Missed On Wall Street On Wednesday
- 07/20/22
- What You Missed On Wall Street This Morning
- 07/11/22
- Early notable gainers among liquid option names on July 11th
- 07/11/22
- Unusually active option classes on open July 11th
- 07/06/22
- Unusually active option classes on open July 6th
- 06/01/22
- Merck put volume heavy and directionally bearish
|
Recommendations
|
Barclays analyst Carter… Barclays analyst Carter Gould raised the firm's price target on Merck to $101 from $97 and keeps an Overweight rating on the shares. The company reported "another beat and raise," driven by Keytruda and Gardasil, Gould tells investors in a research note. ShowHide Related Items >><< - 07/26/22
- Sutro:1st patient dosed in study with Merck for cytokine derivative for cancer
- 07/26/22
- Astellas Pharma, Seagen announce topline results from EV-103 trial
- 07/20/22
- Merck says Phase 3 KEYNOTE-412 trial did not meet primary endpoint of EFS
- 07/18/22
- Merck to stop Phase 3 LYNK-003 trial investigating LYNPARZA
- 07/27/22 H.C. Wainwright
- Seagen price target raised to $200 from $170 at H.C. Wainwright
- 07/18/22 UBS
- Merck price target raised to $98 from $76 at UBS
- 07/12/22 H.C. Wainwright
- H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
- 07/08/22 Morgan Stanley
- Merck price target raised to $88 from $87 at Morgan Stanley
- 07/28/22
- Merck narrows FY22 adjusted EPS view to $7.25-$7.35 from $7.24-$7.36
- 07/28/22
- Merck reports Q2 adjusted EPS $1.87, consensus $1.69
- 07/27/22
- Notable companies reporting before tomorrow's open
- 07/27/22
- Senate panel says Merck avoided billions in U.S. taxes on Keytruda, Reuters says
- 07/15/22
- Merck deal for Seagen unlikely to be completed by earnings, WSJ reports
- 07/07/22
- Merck offers around $200 per share for Seagen, FT reports
- 07/07/22
- Merck in advanced talks to buy Seagen for $40B+, WSJ reports
- 07/28/22
- What You Missed On Wall Street On Thursday
- 07/28/22
- What You Missed On Wall Street This Morning
- 07/20/22
- What You Missed On Wall Street On Wednesday
- 07/20/22
- What You Missed On Wall Street This Morning
- 07/11/22
- Early notable gainers among liquid option names on July 11th
- 07/11/22
- Unusually active option classes on open July 11th
- 07/06/22
- Unusually active option classes on open July 6th
- 06/01/22
- Merck put volume heavy and directionally bearish
|